Article
Cell Biology
Min Liu, Feng Wei, Jian Wang, Wenwen Yu, Meng Shen, Ting Liu, Dong Zhang, Yang Wang, Xiubao Ren, Qian Sun
Summary: MDSCs activate the PI3K/AKT/NF-kappa B pathway in B cells via the PD-1/PD-L1 axis, regulating the immunosuppressive function of Bregs. Inhibition of PD-1/PD-L1 or PI3K/AKT signaling suppresses tumor growth and the immunosuppressive functions of Bregs. Dual suppression of PD-1/PD-L1 and PI3K/AKT shows better antitumor effect.
CELL DEATH & DISEASE
(2021)
Review
Immunology
Youliang Zhao, Yaqian Qu, Changfu Hao, Wu Yao
Summary: Fibrosis is a pathological process characterized by excessive accumulation of extracellular matrix, leading to permanent scarring and organ failure. The immune system, particularly the immune checkpoint molecule PD-1/PD-L1 axis, plays a crucial role in the initiation and progression of fibrosis. The therapeutic targeting of PD-1/PD-L1 axis for tumor immunotherapy has provided new insights for its potential use in fibrotic diseases. This review discusses the structure, function, and regulatory mechanism of PD-1 and PD-L1, and summarizes the research progress of PD-1/PD-L1 signaling in fibrotic diseases.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Cell Biology
Elena Jachetti, Sabina Sangaletti, Claudia Chiodoni, Roberto Ferrara, Mario P. Colombo
Summary: Immuno checkpoint blockade targeting the PD-1/PD-L1 axis has been a major breakthrough in cancer treatment, but not all patients benefit from it. The tumor microenvironment, including MDSCs and their expression of PD-L1, can influence resistance to ICB therapy.
CELLULAR IMMUNOLOGY
(2021)
Review
Oncology
Yasser Tabana, Isobel S. Okoye, Arno Siraki, Shokrollah Elahi, Khaled H. Barakat
Summary: Breast cancer poses a significant global problem, with recent focus on immunotherapy as a new approach to treatment. However, there are limitations to immune checkpoint inhibitors in treating breast cancer, leading researchers to explore novel immunological targets to modulate the tumor immune microenvironment.
FRONTIERS IN ONCOLOGY
(2021)
Review
Immunology
Yanxin Xu, Chen Chen, Yaxin Guo, Shengyun Hu, Zhenqiang Sun
Summary: This article summarizes the application and potential of CRISPR/Cas9 gene editing technology in tumor immunotherapy, as well as its importance in exploring tumor immune regulation mechanisms and clinical practice.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Oncology
Thamiris Becker Scheffel, Nathalia Grave, Pedro Vargas, Fernando Mendonca Diz, Liliana Rockenbach, Fernanda Bueno Morrone
Summary: Glioblastoma is a highly malignant subtype of glioma, and the immune landscape within the tumor microenvironment plays a crucial role in influencing therapy outcomes. The presence of multiple immunosuppression pathways, particularly the adenosine pathway, poses significant obstacles to immune-based cancer therapies and can contribute to treatment resistance. Research focusing on immune checkpoints and the adenosine pathway may provide insights into potential targets for improving tumor treatment strategies.
FRONTIERS IN ONCOLOGY
(2021)
Review
Immunology
Yiru Long, Xiaolu Yu, Runqiu Chen, Yongliang Tong, Likun Gong
Summary: With programmed death 1/ligand 1 (PD-1/PD-L1) as the cornerstone, anti-PD antibodies have revolutionized immunotherapies for malignancies. However, many patients fail to respond to anti-PD treatment due to resistance or hyperprogression. The study highlights the importance of noncanonical PD-1/PD-L1 expression in various cancers and its impact on the efficacy of anti-PD antibodies.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Chemistry, Medicinal
Fabian Krutzek, Klaus Kopka, Sven Stadlbauer
Summary: Immune checkpoint inhibitor (ICI) therapy is emerging as a major treatment option for various cancers. PD-1 and PD-L1 are key targets for ICI, with PD-L1 serving as a reproducible biomarker for therapy decisions and monitoring success. However, PD-L1 expression is heterogeneous and dynamic, making standard diagnostics inadequate. Molecular imaging techniques like PET and SPECT offer advantages in addressing the challenges of heterogeneous checkpoint expression over time. This article provides an overview of existing imaging agents and discusses their pros and cons. Possible future directions for developing new imaging agents for PD-1/PD-L1 status in cancer patients are also presented.
Article
Chemistry, Medicinal
Philippe Bertrand
Summary: Aptamers have emerged as potential alternatives to antibodies or small molecules for targeting immune check points such as PD-1 and PD-L1. They possess high affinity for a wide range of targets including small molecules, proteins, and cells. The SELEX method is used to identify and modify aptamers for specific purposes, and their applications extend to therapy and alternative assay technologies. Strategies for managing aptamer plasma stability can be employed. This perspective provides an overview of the development of aptamers targeting immune checkpoint modulators and other immuno-related targets.
JOURNAL OF MEDICINAL CHEMISTRY
(2023)
Article
Pharmacology & Pharmacy
Maryam Nakhjavani, Sarah Shigdar
Summary: Triple-negative breast cancer (TNBC) has the worst prognosis among breast cancer subtypes and lacks targeted therapy. Immunotherapy targeting PD-1/PD-L1 has shown promise. Aptamers, with their better tissue penetration and lower production cost compared to mAbs, present a potential pathway for PD-1/PD-L1 modulation in the future.
PHARMACOLOGICAL RESEARCH
(2022)
Review
Immunology
Xuan Zhao, Yulin Bao, Bi Meng, Zijian Xu, Sijin Li, Xu Wang, Rui Hou, Wen Ma, Dan Liu, Junnian Zheng, Ming Shi
Summary: Developing biomarkers for predicting the efficacy of immune checkpoint inhibitor therapies is important for avoiding side effects and economic burden. Current assays evaluating PD-L1 expression are imperfect, but recent studies are advancing the methodologies to improve accuracy. This includes standardization of immunohistochemistry tests and the use of novel in vivo probes and liquid biopsy. Considering PD-L1 expression on non-tumor cells and utilizing artificial intelligence can further enhance the predictive accuracy of PD-L1 as a biomarker.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Cell Biology
Benhui Liang, Ximin Hu, Yinghe Ding, Mujun Liu
Summary: The binding of PD-1 to its ligand PD-L1 is crucial for maintaining the non-reactivity of T cells, while tumor cells restrict cellular immune response by highly expressing PD-L1. TEXs can carry PD-L1 and regulate the PD-1/PD-L1 axis to promote tumor progression.
JOURNAL OF CELLULAR PHYSIOLOGY
(2021)
Article
Oncology
Yangyang Zhang, Lingxiu Zeng, Meng Wang, Zhenwei Yang, Hailin Zhang, Liping Gao, Ranran Zhang, Jialong Liu, Wenqing Shan, Ying Chang, Lan Liu, Qiu Zhao, Yong Li, Jing Liu
Summary: The study found that RIG-I plays an important role in the immunotherapy of colon cancer by maintaining the stability of PD-L1 to promote immune evasion. Silencing RIG-I increases the sensitivity of tumor cells to T cell killing and slows down the growth of colon tumors. High expression of RIG-I promotes tumor progression and enhances the sensitivity to PD-1 therapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Biochemistry & Molecular Biology
Yufan Qiu, Yi Yang, Riyao Yang, Chunxiao Liu, Jung-Mao Hsu, Zhou Jiang, Linlin Sun, Yongkun Wei, Chia-Wei Li, Dihua Yu, Jin Zhang, Mien-Chie Hung
Summary: The study reveals that PD-1 can be secreted in an exosomal form by activated T cells and interact remotely with PD-L1. This interaction can attenuate the suppression of tumor-specific cytotoxic T cell activity by PD-L1, restoring tumor surveillance.
Article
Chemistry, Multidisciplinary
Zikuan Gu, Shuxin Xu, Zhanchen Guo, Zhen Liu
Summary: This study presents a molecularly imprinted polymer-based PD-1 nano inhibitor, which effectively blocks the PD-1/PD-L1 signaling pathway with good specificity and high affinity. The inhibitor can reactivate T cells and reverse the chemoresistance of tumor cells, providing a promising option for cancer immunotherapy.
Article
Biochemistry & Molecular Biology
Qian Sun, Shuzhan Li, Yanan Wang, Haiyong Peng, Xiying Zhang, Yu Zheng, Chunjia Li, Li Li, Rongrong Chen, Xinxin Chen, Wenjing Bai, Xiangli Jiang, Liang Liu, Feng Wei, Boshi Wang, Yu Zhang, Hui Li, Xiubao Ren, Hongbing Zhang
CELL DEATH AND DIFFERENTIATION
(2018)
Article
Oncology
Man Li, Yang Wang, Feng Wei, Xiumei An, Naining Zhang, Shui Cao, Baozhu Ren, Xinwei Zhang, Xiubao Ren
JOURNAL OF BREAST CANCER
(2018)
Article
Oncology
Kaiyuan Wang, Yu Zheng, Yinli Yang, Jian Wang, Baihui Li, Feng Wei, Hongwei Zhao, Xiubao Ren
FRONTIERS IN ONCOLOGY
(2019)
Article
Oncology
Congfang Guo, Hua Zhao, Yu Wang, Shuai Bai, Zizhong Yang, Feng Wei, Xiubao Ran
FRONTIERS IN ONCOLOGY
(2019)
Article
Cell Biology
Qian Sun, Xiying Zhang, Limei Wang, Xujie Gao, Yanjuan Xiong, Liang Liu, Feng Wei, Lili Yang, Xiubao Ren
CELL DEATH & DISEASE
(2019)
Article
Radiology, Nuclear Medicine & Medical Imaging
Yang Wang, Ning Zhao, Zhanbo Wu, Na Pan, Xuejie Shen, Ting Liu, Feng Wei, Jian You, Wengui Xu, Xiubao Ren
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2020)
Article
Oncology
Zhenzhen Hui, Feng Wei, Hongliang Ren, Wengui Xu, Xiubao Ren
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2020)
Article
Cell Biology
Min Liu, Feng Wei, Jian Wang, Wenwen Yu, Meng Shen, Ting Liu, Dong Zhang, Yang Wang, Xiubao Ren, Qian Sun
Summary: MDSCs activate the PI3K/AKT/NF-kappa B pathway in B cells via the PD-1/PD-L1 axis, regulating the immunosuppressive function of Bregs. Inhibition of PD-1/PD-L1 or PI3K/AKT signaling suppresses tumor growth and the immunosuppressive functions of Bregs. Dual suppression of PD-1/PD-L1 and PI3K/AKT shows better antitumor effect.
CELL DEATH & DISEASE
(2021)
Article
Immunology
Zhenzhen Hui, Jiali Zhang, Yu Zheng, Lili Yang, Wenwen Yu, Yang An, Feng Wei, Xiubao Ren
Summary: The study successfully expanded Treg cells from colorectal cancer patients using a rapamycin-based in vitro procedure, and conducted single-cell sequencing to explore Treg cell characteristics. The findings revealed distinct transcriptomic features of different subsets of Treg cells, highlighting the potential for alternative therapeutic strategies in autoimmune disease and cancer.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Cell Biology
Cihui Yan, Jingjing Chang, Xinmiao Song, Ying Qi, Zhenyu Ji, Ting Liu, Wenwen Yu, Feng Wei, Lili Yang, Xiubao Ren
Summary: The study revealed that MSCs from lung cancer promoted tumor metastasis and tumorigenesis by inducing partial EMT and upregulating stem cell-related genes in lung cancer cells. These findings suggest that LC-MSCs may serve as potential targets or vehicles for lung cancer therapy.
Article
Oncology
Kaiyuan Wang, Jian Wang, Ting Liu, Wenwen Yu, Nan Dong, Chen Zhang, Wenbin Xia, Feng Wei, Lili Yang, Xiubao Ren
Summary: The study found that M3G can promote PD-L1 expression in NSCLC cells through the TLR4 pathway, affect the cytotoxicity of CTL through the PI3K signaling pathway, and thus promote tumor immune escape. Additionally, M3G can also promote tumor growth and metastasis.
CANCER BIOLOGY & MEDICINE
(2021)
Review
Oncology
Ziqing Zeng, Feng Wei, Xiubao Ren
CANCER BIOLOGY & MEDICINE
(2020)
Meeting Abstract
Immunology
F. Wei, X. Ren
EUROPEAN JOURNAL OF IMMUNOLOGY
(2019)
Article
Oncology
Cihui Yan, Jingjing Chang, Xinmiao Song, Fan Yan, Wenwen Yu, Yang An, Feng Wei, Lili Yang, Xiubao Ren
CANCER BIOLOGY & MEDICINE
(2019)
Article
Oncology
Ziqing Zeng, Fan Yang, Yunliang Wang, Hua Zhao, Feng Wei, Peng Zhang, Xiying Zhang, Xiubao Ren